SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology ($GSIT) is trending due to news highlighting their Compute-In-Memory APU achieving GPU-class AI performance with significantly lower energy costs, sparking community interest in its potential to compete with industry giants like NVDA. Discussions revolve around the APU's performance and energy efficiency, with some viewing GSIT as an overlooked player in the AI and drone sectors due to its exposure to high-speed memory solutions and defense contracts.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending after announcing plans to explore rare earth production at its U.S. mining sites, potentially making it a key player in America's push for critical mineral independence. The community is discussing the company's strategic shift from steel to strategic minerals, with some believing it's a smart move given China's tightening export controls, while others express skepticism and focus on debt reduction.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending as community members discuss the potential impact of the FDA accepting the resubmission of its Biologics License Application for RP1, a melanoma treatment. The news has sparked debate about future prospects, regulatory flexibility, and potential market moves. Discussions also include Wedbush's updated rating and price target.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending due to positive data released by partner GenFleet Therapeutics regarding their lung cancer drug GFH375, showing promising response rates in NSCLC patients. The community is discussing the potential implications of these results, including a possible short squeeze, buyout scenarios, and comparing VSTM to competitors like RVMD. There is optimism regarding upcoming catalysts, such as presentations, NCCN decisions, and potential partnerships.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

RAPT Therapeutics is trending following the announcement of positive topline data from its Phase 2 trial of RPT904 in Chronic Spontaneous Urticaria, leading to discussions about potential price targets and the strength of the biotech momentum. However, some community members are expressing concerns about potential offerings and drops, while others remain optimistic about the company's future and potential breakouts. The stock is also being mentioned in connection with other trending stocks and potential squeeze opportunities.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Corbus Pharmaceuticals Holdings Inc

CRBP is trending amid discussions of market manipulation and a significant drop from pre-market highs, despite recent analyst upgrades and price targets. The community is actively debating the impact of upcoming catalysts and data releases, particularly around CRB-701, while also noting the high institutional ownership and short interest. Overall, conversation is centered on the potential for a rebound following an overreaction to news in the broader sector, with some seeing it as a buying opportunity.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending due to positive Phase 3 breast cancer trial data, sparking discussions about its potential as a new standard of care and a possible buyout target. Community members are analyzing the company's financials and debating the likelihood of a near-term offering, with some anticipating significant upside and others expressing caution about a potential pullback. Overall, there is excitement about the company's prospects within the biotech sector.

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Exelixis is trending due to discussions around unusual options activity and potential bullish setups, including a possible short squeeze due to high short interest. Community members are also focused on the company's long-term potential, driven by its commercial product and pipeline updates, with some viewing it as a possible acquisition target. Recent analyst ratings and target price adjustments are contributing to the increased attention on the stock.

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp

BGLC is trending due to a recently announced strategic partnership term sheet, sparking excitement around potential growth. The community is actively discussing the company's low float and potential for a significant run, with some highlighting its past as a known runner. Community members also point to the company's Ethereum-focused treasury strategy as a potential catalyst.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

DCTH is trending due to discussions around recent earnings and future revenue guidance, which some perceive as weak despite strong data from the CHOPIN trial. The community is debating the impact of seasonality on patient enrollment and potential delays in Hepzato treatments, as well as trial costs and the possibility of dilution. Some investors remain optimistic about the long-term potential of the company's platform and the undervalued nature of their surgical network.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Richtech Robotics and Lululemon have been highlighted as Zacks Bull and Bear of the Day

Richtech Robotics Surges on Growth Hopes While Lululemon Sees Decline.

US Slashes EU Vehicle Tariffs to 15% Under New Trade Terms

The United States cuts EU vehicle tariffs to 15% retroactive to Aug. 1, as automakers like Volkswagen, Porsche, Mercedes, and Renault lower outlooks.

IAA Mobility 2025: Volkswagen, BMW, Mercedes, BYD & XPeng Shine

IAA Mobility 2025 in Munich showcased VWAGY, BMW, MBGYY, BYDDY and XPEV, highlighting the latest EVs, AI tech, and charging innovations.

Smart, the joint venture between Mercedes-Benz and China’s Geely, will launch a new two-seat electric vehicle in late 2026 as the successor to its ForTwo city car.The model, called the Smart #2, will be introduced in China, Europe and other overseas markets. It will be a two-door, two-seat vehicle positioned in the A-segment, the company said.The car is being designed by Mercedes-Benz and engineered on a new architecture developed by Smart’s R&amp;D team for ultra-compact models. Production will take place in China.The #2 will join the existing Smart #1, #3 and #5 in the brand’s lineup. Current Smart models in mainland China are priced between 154,900 yuan ($21,700) and 368,000 yuan, CnEVPost&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://cnevpost.com/2025/09/02/smart-2-debut-2026/">reported</a>.Global CEO Tong Xiangbei said developing an ultra-compact EV on a new architecture was more complex than building larger cars, but added that the company was now ready after strengthening its production and development capabilities.The first Smart ForTwo&nbsp;was launched in 1998 and has sold over 2 million cars globally. In 2020, Mercedes-Benz reached an agreement with Chinese automaker Geely to give Smart a fresh start, with the two companies establishing a joint venture in Ningbo, Zhejiang.&nbsp;Under the deal, Mercedes handles the design while Geely takes care of engineering and production.On Stocktwits, retail sentiment for Geely was ‘bullish’ amid ‘low’ message volume.<a href="https://stocktwits.com/symbol/GELYY">Geely’s U.S.-listed stock</a> has risen 37.3% so far in 2025.($1=7.12 yuan)For updates and corrections, email newsroom[at]stocktwits[dot]com.

A smart brand new energy intelligent electric vehicle jointly owned by Mercedes-Benz and Geely Auto Group is displayed inside China's first new energy vehicle block. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Geely And Mercedes To Bring Back Two-Seater Legacy With Smart #2 EV In 2026

The Smart #2 will be designed by Mercedes-Benz, engineered and built by Geely in China, and sold in China, Europe and other overseas markets.

Equity

European stocks slip marginally lower; earnings, growth data in focus

UK's 650 Million GBP Electric Car Grant: But Will It Be Enough?

UK's 650M GBP Electric Car Grant offers up to 3,750 GBP off EVs under 37,000 GBP. Will automakers and chargers keep pace?

German carmaker shares fall after Trump tariff announcement

Investing.com -- Shares of German automakers fell on Monday after U.S. President Donald Trump threatened sweeping new tariffs on European imports, with no exemptions for autos, which are already subject to a 27.5% duty.

Bernstein flags growing divide in global EV market in 2025 outlook

UBS lifts European auto stock targets as tariff impact eases

Mercedes-Benz warns on cars margin, shares fall after cautious Q2 update

Mercedes-Benz Group AG engages in the business of manufacturing and distributing premium cars. It operates through the following segments: Mercedes-Benz Cars, Mercedes-Benz Vans, and Mercedes-Benz Mobility. The Mercedes-Benz Cars segment includes the brands Mercedes-AMG, Mercedes-Maybach, and Mercedes-EQ. The Mercedes-Benz Vans segment focuses on selling vans under the Mercedes-Benz brand. The Mercedes-Benz Mobility segment is involved in supporting the sales of the vehicle brands. The company was founded by Gottlieb Daimler and Carl Benz in 1926 and is headquartered in Stuttgart, Germany.

Mercedes-Benz Group AG - ADR - Unsponsored

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

MBGYY
Mercedes-Benz Group AG - ADR - Unsponsored

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MBGYY News

MBGYYMercedes-Benz Group AG - ADR - Unsponsored